ProQR Therapeutics N.V.
PRQR Healthcare Biotechnology
ProQR Therapeutics N.V.’s revenue for fiscal 2025 (year ended December 2025) was $18.0 million, down 12.0% from fiscal 2024. In the quarter to June 2026, revenue grew 135.0%, EPS grew 28.6%, free cash flow fell 1.06% and total debt rose 8.71%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PRQR
ProQR Therapeutics N.V. (PRQR) P/E ratio
ProQR Therapeutics N.V. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 17 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LYEL Lyell Immunopharma, Inc. compare | n/m |
| IFRX InflaRx N.V. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| RNAC Cartesian Therapeutics, Inc. compare | n/m |
| IVVD Invivyd, Inc. compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| PRQR ProQR Therapeutics N.V. | n/m |
| CGEN Compugen Ltd. compare | 5.2× |
| NAGE Niagen Bioscience, Inc. compare | 12.5× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)